



December 20, 2021

British Columbia Securities Commission

Dear Sirs/Mesdames:

Re: Pharmala Biotech Holdings Inc. (the "Company")

We refer to the final prospectus of Pharmala Biotech Holdings Inc. dated December 20, 2021 (the "Prospectus").

We consent to being named and to the use, through incorporation in the above-mentioned Prospectus, of our audit report to the shareholders of Pharmala Biotech Holdings Inc. dated December 20, 2021 on the following financial statements:

- Consolidated statements of financial position as at August 31, 2021;
- Consolidated statements of loss and comprehensive loss, consolidated statements of changes in equity and consolidated statements of cash flows for the period from December 23, 2020 (date of incorporation) to August 31, 2021; and
- Notes comprising a summary of the significant accounting policies and other explanatory information.

We report that we have read the Prospectus and all information specified therein and have no reason to believe that there are any misrepresentations in the information contained therein that are derived from the consolidated financial statements upon which we have reported or that are within our knowledge as a result of our audit of such financial statements. We have complied with Canadian generally accepted standards for an auditor's consent to the use of a report of the auditor included in an offering document, which does not constitute an audit or review of the Prospectus as these terms are described in the CPA Canada Handbook – Assurance.

Yours very truly

Clearhouse LLP

Chartered Professional Accountants
Licensed Public Accountants